Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer

Registration and Randomization - Inclusion Criteria

• Women or men
• ≥18 years of age
• Histologically or cytologically confirmed adenocarcinoma of the breast and clinical evidence of metastatic breast cancer.
• Pre-treatment requirements:

4.1. Must have been previously treated in neoadjuvant, adjuvant or metastatic setting with anthracycline and/or taxane.

4.2. Must have received 2-3 prior chemotherapy treatment regimens NOTE: If NO prior (neo)adjuvant chemotherapy, patient must have received a minimum of 2 prior chemotherapy regimens in the metastatic setting.

4.2.1 NOTE: If prior (neo)adjuvant chemotherapy HAS been given, patient must have received at least 1 prior chemotherapy regimen in the metastatic setting.

4.3. Prior hormonal therapy allowed in the neo-adjuvant, adjuvant, or metastatic setting.

Unlimited prior hormonal therapy is allowed.

• Patients must have measurable disease as defined in the protocol.
• Negative pregnancy test done ≤7 days prior to registration, for women of childbearing potential only.
• The following laboratory values obtained ≤15 days prior to registration.

7.1 Hemoglobin ≥10.0g/dL

7.2 ANC ≥1500/mm^3

7.3 Platelet count ≥100,000/mL

7.4 Total bilirubin ≤1.5 x ULN)

7.5 SGOT (AST) and SGPT (ALT) ≤5 x ULN

7.6 Serum creatinine ≤1.5 x ULN

• LVEF ≥50% and EKG within institutional normal limits completed ≤22 days prior to registration.
• ECOG Performance Status (PS) of 0, 1 or 2.
• Life expectancy >3 months
• Ability to complete questionnaire(s) by themselves or with assistance.
• Patient has provided written informed consent
• Willingness to return to NCCTG enrolling institution for follow-up.

Registration and Randomization - Exclusion Criteria

• Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown.

1.1 Pregnant women

1.2 Nursing women

1.3 Men or women of childbearing potential who are unwilling to employ adequate contraception (as determined by the treating physician)

• Stage III or IV invasive cancer (other than breast cancer) in ≤3 years prior to registration (with the exception of non-melanoma skin cancer).
• HER2 positive breast cancer (3+ by IHC or FISH amplified) breast cancer by ASCO/CAP guidelines
• Has already received lifetime cumulative treatment with doxorubicin equivalent to >400 mg/m2.
• >3 prior chemotherapy regimens for breast cancer.

5.1 NOTE: This number includes (neo)adjuvant chemotherapy, if given. If (neo)adjuvant chemotherapy HAS been given it counts as one (1) regimen.

• Major surgery, chemotherapy, or immunologic therapy ≤3 weeks prior to registration.

6.1 NOTE: If patient has received prior treatment with bevacizumab, treatment on this trial should not begin until ≥4 weeks after the last dose of bevacizumab.

• Radiotherapy ≤4 weeks prior to registration, except if to a non-target lesion only.

7.1 Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.

7.2 If patient receives single dose radiation for palliation or radiation to non-target lesion, they may immediately proceed to registration without waiting.

7.3 Acute adverse events from radiation must have resolved to ≤Grade 1 (according to current version of NCI CTCAE).

• Evidence of active brain metastasis including leptomeningeal involvement.

8.1 CNS metastasis controlled by prior surgery and/or radiotherapy is allowed. To be considered controlled, there must be at least 2 months of no symptoms or evidence of progression prior to study entry and corticosteroid therapy given to control brain edema must have been discontinued.

• Uncontrolled hypertension (blood pressure [BP] >160/90mmHg on ≥2 occasions at least 5 minutes apart). (Patients who have recently started or adjusted anti-hypertensive medications are eligible providing that BP is <140/90mmHg on any new regimen for ≥3 differen